LivaNova announced that new clinical data for its sutureless surgical aortic valve, Perceval, will be unveiled at this year’s American Association for Thoracic Surgery meeting. On May 4, Prof. Bart Meuris from Leuven University Hospital will present the data from his center’s 11-year clinical experience with Perceval, which represents the longest clinical follow-up for the valve that has been published. The results demonstrate the strong performance of the Perceval valve both in terms of durability and outcomes, which reaffirm its position as a trusted platform. Of particular significance in the findings is the absence of explants due to structural valve deterioration, as well as the low rate of paravalvular leak reported. The retrospective, observational, single-center study included 468 consecutive patients implanted with Perceval between 2007 and 2017: Patient mean age was 79, mean EuroSCORE II was 5.0 and STS score was 5.8. The majority of the cases treated were all-comers, including emergencies. 55% of cases were conducted as part of concomitant procedures, while a high rate of the isolated aortic valve replacement cases was carried out through minimally invasive surgery.
https://thefly.com/landingPageNews.php?id=2903137
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.